AWZ1066S + Placebo
Phase 1Terminated 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Filariasis, Lymphatic
Conditions
Filariasis, Lymphatic, Onchocerciasis
Trial Timeline
Dec 10, 2021 → May 22, 2023
NCT ID
NCT05084560About AWZ1066S + Placebo
AWZ1066S + Placebo is a phase 1 stage product being developed by Eisai for Filariasis, Lymphatic. The current trial status is terminated. This product is registered under clinical trial identifier NCT05084560. Target conditions include Filariasis, Lymphatic, Onchocerciasis.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05084560 | Phase 1 | Terminated |
Competing Products
2 competing products in Filariasis, Lymphatic
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Emodepside (BAY 44-4400) | Bayer | Phase 1 | 30 |
| LSF emodepside (BAY 44-4400) or matching placebo | Bayer | Phase 1 | 30 |